Pantoprazole(Synonyms: 泮托拉唑; BY1023; SKF96022)

发表于由

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。

Pantoprazole (Synonyms: 泮托拉唑; BY1023; SKF96022)

Pantoprazole (BY1023) 是一种具有口服活性的，有效质子泵 (proton pump) 抑制剂 (PPI)。Pantoprazole 是一种取代的苯并咪唑，是一种有效的 H+/K+-ATPase 抑制剂，IC50 为 6.8 μM。Pantoprazo 可以改善 pH 值稳定性，并具有抗分泌，抗溃疡的作用。Pantoprazo 联合阿霉素 (Doxorubicin; HY-15142) 可显着增加肿瘤生长延迟。

Pantoprazole(Synonyms: 泮托拉唑; BY1023; SKF96022)

Pantoprazole Chemical Structure

CAS No. : 102625-70-7

规格 是否有货
100 mg   询价  
250 mg   询价  
500 mg   询价  

* Please select Quantity before adding items.

Pantoprazole 的其他形式现货产品:

Pantoprazole sodium Pantoprazole sodium hydrate

生物活性

Pantoprazole (BY10232) is an orally active and potent proton pump inhibitor (PPI)[1]. Pantoprazole, a substituted benzimidazole, is a potent H+/K+-ATPase inhibitor with an IC50 of 6.8 μM. Pantoprazole improves pH stability and has anti-secretory, anti-ulcer activities. Pantoprazole significantly increased tumor growth delay combined with Doxorubicin (HY-15142)[3][4].

IC50 & Target

proton pump
体外研究
(In Vitro)

Pantoprazole (BY1023; 1-10000 μM) leads to concentration-dependent increases in endosomal pH in EMT-6 and MCF7 cells[1].
Pantoprazole (BY10232) can block exosome release. Pantoprazole (BY10232) inhibits the activity of V-H+-ATPase and impaires the ability of tumour cells (melanomas, adenocarcinomas, and lymphoma cell lines) to acidify the extracellular medium[2]

Shanghai Jinpan Biotech Co Ltd has not independently confirmed the accuracy of these methods. They are for reference only.
体内研究
(In Vivo)

Pantoprazole (BY1023; 200 mg/kg; IP; once a week for 3 weeks) significantly increases tumor growth delay of MCF-7 xenografts combined with Doxorubicin[1].
Pantoprazole (0.3-3 mg/kg, p.o.) dose-dependently decreases both basal acid secretion in pylorus-ligated rats and the stimulated acid secretion induced by mepirizole in acute fistula rats[4].

Shanghai Jinpan Biotech Co Ltd has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Mice bearing MCF-7 or A431 xenografts[1]
Dosage: 200 mg/kg
Administration: IP; once a week for 3 weeks; alone or 2 hours before Doxorubicin (6 mg/kg i.v.)
Result: Showed even greater growth delay of MCF-7 xenografts with Doxorubicin compared with the single-dose combination.
Significantly increased tumor growth delay with a single dose with Doxorubicin.
There is no effect on growth delay alone.

Clinical Trial

分子量

383.37

Formula

C16H15F2N3O4S
CAS 号

102625-70-7
中文名称

泮托拉唑
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.
参考文献

  • [1]. Krupa J Patel, et al. Use of the proton pump inhibitor pantoprazole to modify the distribution and activity of doxorubicin: a potential strategy to improve the therapy of solid tumors. Clin Cancer Res. 2013 Dec 15;19(24):6766-76.

    [2]. Huarui Zhang, et al. Advances in the discovery of exosome inhibitors in cancer. J Enzyme Inhib Med Chem. 2020 Dec;35(1):1322-1330.

    [3]. W Beil, et al. Pantoprazole: a novel H+/K(+)-ATPase inhibitor with an improved pH stability. Eur J Pharmacol. 1992 Aug 6;218(2-3):265-71.

    [4]. K Takeuchi, et al. Effects of pantoprazole, a novel H+/K+-ATPase inhibitor, on duodenal ulcerogenic and healing responses in rats: a comparative study with omeprazole and lansoprazole. J Gastroenterol Hepatol. 1999 Mar;14(3):251-7.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务